Genes that act as brakes to stop the development of an aggressive form of leukaemia have been identified by Edinburgh researchers.
Their findings offer fresh insights into how to tackle the disease and could lead to new therapies that prevent relapses.
Scientists have found that two molecules work together to stop the formation of leukemic stem cells in an aggressive type of blood cancer called Acute Myeloid Leukaemia (AML).
The work was carried out at the University’s MRC Centre for Regenerative Medicine (below) and the Edinburgh Cancer Research Centre. Researchers say that their new results suggest that therapies designed to block these molecules may have no impact or could even worsen disease.
The cancer occurs when production of new blood cells by the bone marrow goes awry.
This leads to the formation of leukemic stem cells, which fuel the disease and provide a constant flow of abnormal leukaemia cells.
The University of Edinburgh study shows that blocking the molecules accelerates the development of leukaemia.
The findings are surprising because previous research had suggested that such blocking may stop leukaemia progression.
Conversely, designing new therapies that promote the activity of the molecules could help to treat AML or stop the disease from recurring after chemotherapy.
Around 2,500 people are diagnosed with AML in the UK each year.
Chemotherapy drugs can help to eliminate leukaemia cells but have no effect on leukemic stem cells that cause the disease.
This means the disease sometimes relapses.
The study is published in the Journal of Experimental Medicine. It was funded by Cancer Research UK, Bloodwise, the Kay Kendall Leukaemia Fund and the Medical Research Council.
Professor Kamil R Kranc, Cancer Research UK Senior Fellow at the MRC Centre for Regenerative Medicine, who led the study, said: "We now intend to harness this knowledge to develop curative therapies that eliminate leukaemic stem cells, which are the underlying cause of AML.”
Dr Milica Vukovic, first author of the study, said: “Leukaemia is an umbrella term for a vast number of very complicated and different diseases.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here